Puma Biotechnology Inc. (PBYI)’s Financial Results Comparing With Eton Pharmaceuticals Inc. (NASDAQ:ETON)

Puma Biotechnology Inc. (NASDAQ:PBYI) and Eton Pharmaceuticals Inc. (NASDAQ:ETON), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Puma Biotechnology Inc. 201.52M 5.11 146.96M -3.90 0.00
Eton Pharmaceuticals Inc. N/A 0.00 18.36M -0.85 0.00

Table 1 highlights Puma Biotechnology Inc. and Eton Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 demonstrates the return on equity, return on assets and net margins of Puma Biotechnology Inc. and Eton Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Puma Biotechnology Inc. -72.93% -301.5% -74.1%
Eton Pharmaceuticals Inc. 0.00% 0% 0%


3 and 3 are the respective Current Ratio and a Quick Ratio of Puma Biotechnology Inc. Its rival Eton Pharmaceuticals Inc.’s Current and Quick Ratios are 8.1 and 8.1 respectively. Eton Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Puma Biotechnology Inc.

Institutional and Insider Ownership

The shares of both Puma Biotechnology Inc. and Eton Pharmaceuticals Inc. are owned by institutional investors at 95.8% and 0% respectively. About 11.3% of Puma Biotechnology Inc.’s share are owned by insiders. Competitively, 32.4% are Eton Pharmaceuticals Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Puma Biotechnology Inc. 3.83% 4.59% -49.57% -50.45% -77.02% -75.59%
Eton Pharmaceuticals Inc. -4.25% 0% 0% 0% 0% -2.72%

For the past year Puma Biotechnology Inc. was more bearish than Eton Pharmaceuticals Inc.


Eton Pharmaceuticals Inc. beats on 7 of the 9 factors Puma Biotechnology Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.